Respiri Limited, an ASX-listed eHealth SaaS company supporting respiratory health management, announced its signing of a service agreement with The Pharmacy Guild of Australia, the national body representing over 5,700 community pharmacies across the country.

The two-year agreement with Guild Learning and Development (GuildEd), the learning destination for all pharmacists, pharmacy assistants, and interns Australia-wide, will see the joint development of a Guild-accredited Continuing Professional Development online training course for pharmacists on optimising asthma patient management, in particular children, including the role of devices in detecting wheeze.

This education program is expected to enhance and support the capability of pharmacists to better help patients diagnosed with asthma optimise care through understanding and complying with their asthma management plans also supported by wheezo eHealth SaaS App, which also effectively monitors asthma wheeze.

“With over 65,000 pharmacists practicing in Australia, Respiri understands their importance in helping patients with asthma better manage their condition, ensuring a better health and quality of life,” said Respiri CEO Marjan Mikel.

“By educating pharmacists, who are an important intermediary between an asthmatic patient and their doctor and who already sell a range of asthmatic devices within the pharmacy setting, we see them as critical determinant in building sales momentum and significant growth within this important channel,” Mikel added. –